{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:16:24Z","timestamp":1782951384749,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-033052"],"award-info":[{"award-number":["INV-033052"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R00 MH121166"],"award-info":[{"award-number":["R00 MH121166"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In Kenya, as in many African countries, private pharmacies are ubiquitous, frequently accessed, and underutilized for the delivery of HIV prevention services. Whether enabling private pharmacies to initiate and manage clients on HIV pre- and post-exposure prophylaxis (PrEP and PEP) leads to greater uptake and continuation than the current standard\u2014pharmacy referral to clinic-based PrEP\/PEP\u2014is unknown. To address this gap and inform how private pharmacies might partner with the public sector, we are testing several models of pharmacy-delivered PrEP\/PEP in comparison to the current standard.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The Pharm PrEP cRCT is a 60-pharmacy, four-arm cluster-randomized controlled trial ongoing in Central and Western Kenya (first enrollment: 26 June 2023). Eligible pharmacies were licensed by the government, had a private room, and were willing to complete research activities (including a 3-day provider training). Study pharmacies were randomized 1:1:1:1 to (1)\n                      <jats:italic>client-sustained delivery<\/jats:italic>\n                      , in which clients pay pharmacies 250 KES (~$2 USD) per PrEP\/PEP visit; (2)\n                      <jats:italic>implementor-sustained delivery<\/jats:italic>\n                      , in which clients pay nothing and implementors pay pharmacies 250 KES per PrEP\/PEP visit; (3)\n                      <jats:italic>implementor-sustained<\/jats:italic>\n                      \u2009+\u2009\n                      <jats:italic>counselor-supported delivery<\/jats:italic>\n                      , in which clients pay nothing, delivery is supported by an HIV testing services (HTS) counselor, and implementors pay pharmacies 100 KES (~$1 USD) per PrEP\/PEP visit; or 4)\n                      <jats:italic>referral (control),<\/jats:italic>\n                      in which clients pay nothing and implementors pay pharmacies 100 KES per referral to clinic-based PrEP\/PEP. Pharmacies delivering PrEP\/PEP receive supporting commodities free from government stock. Primary outcomes are PrEP initiation and continuation (any refilling) reported by clients 60\u00a0days post-enrollment; secondary outcomes include PEP initiation, PEP-to-PrEP transition, repeat PEP use, PrEP\/PEP initiation, and PrEP\/PEP continuation at 60 and 270\u00a0days post-enrollment. Primary analyses will compare each intervention arm to the control; secondary analyses will compare intervention arms to one another. We will additionally assess implementation outcomes (e.g., acceptability, feasibility, cost) from client and provider perspectives.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial will generate evidence on the potential benefits of leveraging private pharmacies for delivery of PrEP and PEP and the relative effectiveness of pharmacy delivery when subsidized by clients, implementors, and\/or supported by HTS counselors. The findings may inform enabling policy and approaches for scale-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT05842122. Registered on\u00a0April 5, 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09384-7","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T02:15:39Z","timestamp":1767060939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Testing different models of pharmacy-based HIV pre- and post-exposure prophylaxis initiation and management in Kenya: protocol for a cluster-randomized controlled trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Tabitha","family":"Kareithi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie D.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Meisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Omollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Ong\u2019wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Harkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kiptinness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peris","family":"Otieno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Juma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel C.","family":"Malen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah O.","family":"Anyona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetika","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Gichuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdaline","family":"Asewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Pintye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Mugambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monisha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Were","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ngure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Bukusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5675-8836","authenticated-orcid":false,"given":"Katrina F.","family":"Ortblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Pharm PrEP cRCT team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"9384_CR1","unstructured":"Joint United Nations Programme on HIV\/AIDS. Global HIV & AIDS statistics \u2014 Fact sheet 2024. Geneva: UNAIDS; 2024. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf. Cited 2024 Dec 6."},{"issue":"5","key":"9384_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"issue":"5","key":"9384_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423\u201334.","journal-title":"N Engl J Med"},{"issue":"27","key":"9384_CR4","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399.","journal-title":"N Engl J Med"},{"key":"9384_CR5","first-page":"1","volume":"1","author":"SD Roche","year":"2021","unstructured":"Roche SD, Wairimu N, Mogere P, Kamolloh K, Odoyo J, Kwena ZA, et al. Acceptability and feasibility of pharmacy-based delivery of pre-exposure prophylaxis in Kenya: a qualitative study of client and provider perspectives. AIDS Behav. 2021;1:1\u20132.","journal-title":"AIDS Behav"},{"key":"9384_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-020-05898-9","volume":"20","author":"KF Ortblad","year":"2020","unstructured":"Ortblad KF, Mogere P, Roche S, Kamolloh K, Odoyo J, Irungu E, et al. Design of a care pathway for pharmacy-based PrEP delivery in Kenya: results from a collaborative stakeholder consultation. BMC Health Serv Res. 2020;20:1\u20139.","journal-title":"BMC Health Serv Res"},{"key":"9384_CR7","unstructured":"National AIDS & STI Control Program, Ministry of Health, Kenya. Kenya HIV prevention and treatment guidelines. Nairobi: National AIDS & STI Control Program; 2022. Available from: https:\/\/www.differentiatedservicedelivery.org\/wp-content\/uploads\/Kenya-ARV-Guidelines-2022-Final-1.pdf. Cited 2024 Dec 6."},{"issue":"1","key":"9384_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/QAI.0b013e318198a96a","volume":"51","author":"AM Siika","year":"2009","unstructured":"Siika AM, Nyandiko WM, Mwangi A, Waxman M, Sidle JE, Kimaiyo SN, et al. The structure and outcomes of a HIV postexposure prophylaxis program in a high HIV prevalence setup in western Kenya. J Acquir Immune Defic Syndr. 2009;51(1):47\u201353.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"9384_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/QAI.0b013e318278ba1b","volume":"62","author":"P Izulla","year":"2013","unstructured":"Izulla P, McKinnon LR, Munyao J, Karanja S, Koima W, Parmeres J, et al. HIV postexposure prophylaxis in an urban population of female sex workers in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2013;62(2):220\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"9384_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25942","volume":"25","author":"J Ayieko","year":"2022","unstructured":"Ayieko J, Petersen ML, Kamya MR, Havlir DV. PEP for HIV prevention: are we missing opportunities to reduce new infections? J Int AIDS Soc. 2022;25(5):e25942.","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"9384_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5114\/hivar.2023.133168","volume":"22","author":"SN Eshun","year":"2023","unstructured":"Eshun SN, Tampah-Naah AM, Udor R, Addae D. Awareness and willingness to use pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) among sexually active adults in Ghana. HIV AIDS Rev. 2023;22(4):329\u201336.","journal-title":"HIV AIDS Rev"},{"key":"9384_CR12","doi-asserted-by":"publisher","unstructured":"Ortblad KF, Mogere P, Bukusi E, Ngure K, Baeten JM. Pharmacy delivery to expand the reach of PrEP in Africa. J Int AIDS Soc. 2020. https:\/\/doi.org\/10.1002\/jia2.25619.","DOI":"10.1002\/jia2.25619"},{"issue":"15","key":"9384_CR13","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.2146\/ajhp080483","volume":"66","author":"SD Pastakia","year":"2009","unstructured":"Pastakia SD, Schellhase EM, Jakait B. Collaborative partnership for clinical pharmacy services in Kenya. Am J Health Syst Pharm. 2009;66(15):1386\u201390.","journal-title":"Am J Health Syst Pharm"},{"key":"9384_CR14","unstructured":"Wairimu N, Roche S, Ortblad K, Mogere P, Kamolloh K, Odoyo J, et al. Building public-private partnerships for pharmacy-based PrEP delivery in Kenya: willingness to collaborate among PrEP and pharmacy providers. Online abstract at HIVR4P 2021: 4th HIV Research for Prevention Conference, Virtual, January 27\u201328 and February 3\u20134, 2021. Abstract PU16.14. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.25659."},{"key":"9384_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26467","volume":"28","author":"SD Roche","year":"2025","unstructured":"Roche SD, Omollo V, Mogere P, Asewe M, Gakuo S, Banerjee P, et al. A modified pharmacy provider\u2010led delivery model of oral HIV pre\u2010and post\u2010exposure prophylaxis in Kenya: a pilot study extension. J Int AIDS Soc. 2025;28:e26467.","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"9384_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26131","volume":"26","author":"KF Ortblad","year":"2023","unstructured":"Ortblad KF, Mogere P, Omollo V, Kuo AP, Asewe M, Gakuo S, et al. Stand\u2010alone model for delivery of oral HIV pre\u2010exposure prophylaxis in Kenya: a single\u2010arm, prospective pilot evaluation. J Int AIDS Soc. 2023;26(6):e26131.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"9384_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11904-024-00696-y","volume":"21","author":"SD Roche","year":"2024","unstructured":"Roche SD, Were D, Crawford ND, Tembo A, Pintye J, Bukusi E, et al. Getting HIV pre-exposure prophylaxis (PrEP) into private pharmacies: global delivery models and research directions. Curr HIV AIDS Rep. 2024;21(3):116\u201330.","journal-title":"Curr HIV AIDS Rep"},{"key":"9384_CR18","doi-asserted-by":"crossref","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","DOI":"10.1136\/bmj.e7586"},{"key":"9384_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26245","volume":"27","author":"R Banadakoppa Manjappa","year":"2024","unstructured":"Banadakoppa Manjappa R, Bhattacharjee P, Shaw SYN, Gitonga J, Kioko J, Songok F, et al. A sub\u2010national HIV epidemic appraisal in Kenya: a new approach for identifying priority geographies, populations and programmes for optimizing coverage for HIV prevention. J Int AIDS Soc. 2024;27:e26245.","journal-title":"J Int AIDS Soc"},{"key":"9384_CR20","unstructured":"World Health Organization. Oral PrEP Tool app. Geneva: WHO; 2018. Available from: https:\/\/www.who.int\/news\/item\/04-12-2018-oral-prep-tool-app. Cited 2024 Dec 6."},{"key":"9384_CR21","unstructured":"National AIDS & STI Control Program, Ministry of Health, Kenya. Kenya HIV Testing Services Operational Manual. Nairobi: National AIDS & STI Control Program; 2022. Available from: https:\/\/www.prepwatch.org\/wp-content\/uploads\/2023\/04\/Kenya-HTS-Manual.pdf. Cited 2024 Dec 6."},{"key":"9384_CR22","unstructured":"National AIDS & STI Control Program. Private Sector Engagement Framework for Delivery of HIV Services in Kenya. Nairobi: National AIDS & STI Control Program; 2023. Available from: https:\/\/cdn.prod.website-files.com\/63ff2c1bed17e622bce9c2ea\/651a8eba2d5bb9fc0740c66a_Private%20Sector%20Engagement%20%20Framework%20-Kenya.pdf. Cited 2024 Dec 6."},{"key":"9384_CR23","doi-asserted-by":"crossref","unstructured":"Ekwunife OI, Kuo A, Zhang S, Banerjee P, Kiptinness C, Omollo V, Chen Y, Roche S, Odoyo J, Bukusi EA, Ngure K, Ortblad KF. Understanding the cost of pharmacy-delivered HIV pre- and post-exposure prophylaxis in Kenya: findings from pilot studies. BMC Health Serv Res. 2025;15(1):1536.","DOI":"10.1186\/s12913-025-13681-x"},{"key":"9384_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.12688\/gatesopenres.13342.1","volume":"5","author":"D Were","year":"2021","unstructured":"Were D, Musau A, Mugambi M, Plotkin M, Kabue M, Manguro G, et al. An implementation model for scaling up oral pre-exposure prophylaxis in Kenya: Jilinde project. Gates Open Res. 2021;5:113.","journal-title":"Gates Open Res"},{"key":"9384_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26468","volume":"28","author":"C Kiptinness","year":"2025","unstructured":"Kiptinness C, Naik P, Kareithi T, Thuo N, Okello P, Culquichicon C, et al. Online delivery of oral HIV pre\u2010and post\u2010exposure prophylaxis: findings from the ePrEP Kenya pilot. J Int AIDS Soc. 2025;28:e26468.","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"9384_CR26","doi-asserted-by":"publisher","first-page":"e1730","DOI":"10.1016\/S2214-109X(21)00391-0","volume":"9","author":"EM Irungu","year":"2021","unstructured":"Irungu EM, Mugwanya KK, Mugo NR, Bukusi EA, Donnell D, Odoyo J, et al. Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: a pragmatic stepped-wedge randomised trial. Lancet Glob Health. 2021;9(12):e1730\u20139.","journal-title":"Lancet Glob Health"},{"issue":"10","key":"9384_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26177","volume":"26","author":"KF Ortblad","year":"2023","unstructured":"Ortblad KF, Kwach B, Zhang S, Asewe M, Ongwen PA, Malen RC, et al. Measuring the performance of HIV self\u2010testing at private pharmacies in Kenya: a cross\u2010sectional study. J Int AIDS Soc. 2023;26(10):e26177.","journal-title":"J Int AIDS Soc"},{"key":"9384_CR28","unstructured":"Maisha Meds. Using technology to transform health care in Africa 2024. Nairobi: Maisha Meds; 2024. Available from: https:\/\/maishameds.org\/."},{"issue":"1","key":"9384_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-022-07577-3","volume":"22","author":"M Sekhon","year":"2022","unstructured":"Sekhon M, Cartwright M, Francis JJ. Development of a theory-informed questionnaire to assess the acceptability of healthcare interventions. BMC Health Serv Res. 2022;22(1):1\u201312.","journal-title":"BMC Health Serv Res"},{"issue":"8","key":"9384_CR30","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1016\/j.sapharm.2021.11.011","volume":"18","author":"SR Carter","year":"2022","unstructured":"Carter SR, Ng R, El-Den S, Schneider CR. A patient-reported experience measure for community pharmacy including development of a short-form: the perceived service quality scale. Res Social Adm Pharm. 2022;18(8):3369\u201378.","journal-title":"Res Social Adm Pharm"},{"issue":"1","key":"9384_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0635-3","volume":"12","author":"BJ Weiner","year":"2017","unstructured":"Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, et al. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017;12(1):108.","journal-title":"Implement Sci"},{"issue":"1","key":"9384_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-021-01105-3","volume":"16","author":"CJ Miller","year":"2021","unstructured":"Miller CJ, Barnett ML, Baumann AA, Gutner CA, Wiltsey-Stirman S. The FRAME-IS: a framework for documenting modifications to implementation strategies in healthcare. Implement Sci. 2021;16(1):36.","journal-title":"Implement Sci"},{"issue":"2","key":"9384_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/ije\/28.2.319","volume":"28","author":"RJ Hayes","year":"1999","unstructured":"Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. Int J Epidemiol. 1999;28(2):319\u201326.","journal-title":"Int J Epidemiol"},{"issue":"11","key":"9384_CR34","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1007\/s10461-016-1406-x","volume":"20","author":"IB Wilson","year":"2016","unstructured":"Wilson IB, Lee Y, Michaud J, Fowler FJ Jr, Rogers WH. Validation of a new three-item self-report measure for medication adherence. AIDS Behav. 2016;20(11):2700\u20138.","journal-title":"AIDS Behav"},{"issue":"2","key":"9384_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"9384_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-016-0217-0","volume":"16","author":"C Pedroza","year":"2016","unstructured":"Pedroza C, Truong VT. Performance of models for estimating absolute risk difference in multicenter trials with binary outcome. BMC Med Res Methodol. 2016;16:1\u201312.","journal-title":"BMC Med Res Methodol"},{"key":"9384_CR37","unstructured":"Vassall A, Sweeney S, Kahn J, Gomez GB, Bollinger L, Marseille E, et al. Reference case for estimating the costs of global health services and interventions. Global Health Cost Consortium. Sept 12, 2017. https:\/\/ghcosting.org\/pages\/standards\/reference_case.php. Accessed 30 Oct 2025."},{"issue":"1","key":"9384_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01245-0","volume":"17","author":"LJ Damschroder","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated consolidated framework for implementation research based on user feedback. Implement Sci. 2022;17(1):75.","journal-title":"Implement Sci"},{"issue":"1","key":"9384_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-7-37","volume":"7","author":"J Cane","year":"2012","unstructured":"Cane J, O\u2019Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7(1):37.","journal-title":"Implement Sci"},{"key":"9384_CR40","unstructured":"Joint United Nations Programme on HIV\/AIDS. Good participatory practice: guidelines for biomedical HIV prevention trials. Geneva: UNAIDS; 2007. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/JC1853_GPP_Guidelines_2011_en_0.pdf."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09384-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09384-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09384-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:27:26Z","timestamp":1770035246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-025-09384-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9384"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09384-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5968938\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial protocol (version 2.1, December 18, 2024), informed consent scripts, surveys and interview guides, and recruitment materials have all been approved by the Scientific Ethics Review Unit at KEMRI (Nairobi, Kenya) and the Institutional Review Board at Fred Hutch (Seattle, USA) (Additional files 4, 5, and 6). All participants provide informed consent prior to enrollment. Consent for clients is verbal and conducted over the phone with a research assistant following a consent script; consent for all provider types is written. In the consent forms, we clarify that study data may be used in future studies, and study participation is optional and may be discontinued at any point. Any potential protocol modifications will be reviewed and approved by our ethics boards before implementation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}